Serina Therapeutics (SER) Insider Wilson Buys $8.9K of Stock
Karen Wilson added 5,100 shares of SER to her portfolio on June 11, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Karen Wilson bought 5,100 shares of Serina Therapeutics, Inc. ($SER) at an average price of $1.75, worth about $8,925, on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SER is up 16.0% after 1 week, up 13.3% after 1 month and down 5.0% to date (from the $1.81 close on Jun 11, 2026).
SER
Serina Therapeutics, Inc.
Key Points
- Karen Wilson purchased 5,100 shares of SER at $1.75 each, totaling $8,925 on June 11, 2026.
- Shares of SER traded around $1.93, with several institutional investors adjusting their positions.
- HC Wainwright reiterated a buy rating on SER with a $15 price target as of August 28, 2025.
Get $SER trade alerts by text
We text you when insiders, Congress or big funds trade $SER. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Serina Therapeutics, Inc. alert may contain errors. Disclosures
Karen Wilson added 5,100 shares of SER to her holdings on June 11, 2026, paying $1.75 per share. The transaction amounted to $8,925, showing Wilson's continued interest in the company.
What Changed in Karen Wilson's SER Position
Wilson's recent purchase on June 11 follows several other acquisitions, including 10,000 shares on May 22 and 5,000 shares on June 12. Her actions indicate a growing stake in the company, although her precise role within SER isn't specified.
Other Institutional Activity in SER
Several institutional investors have also been active in SER. SIO Capital Management, LLC added 1 million shares, bringing its total to 1 million shares valued at approximately $1.94 million. Vanguard Capital Management LLC picked up 159,136 shares, reaching a total of 159,136 shares worth about $308,724. Meanwhile, Geode Capital Management, LLC increased its holdings by 34,564 shares to a total of 64,973 shares, valued at $126,049. BlackRock, Inc. also boosted its position by 41,015 shares, ending with 58,264 shares worth $113,033.
Serina Therapeutics, Inc. Stock Down 14.2%
Shares of SER traded at around $1.93. The stock has seen activity from various investors, reflecting interest in its performance and potential.
Insider Buying and Selling at Serina Therapeutics, Inc.
Karen Wilson was not the only insider buying shares recently. Steven Ledger, the CEO, purchased 10,100 shares at $1.93 on May 26, 2026. Gregory Curhan, the CFO, and Randall Moreadith, the Chief Scientific Officer, also acquired significant shares in late May.
Analysts Set New Price Targets
Analysts have shown optimism about SER's potential. On August 28, 2025, HC Wainwright & Co. reiterated a buy rating with a $15 price target. Earlier, on March 11, 2025, Jones Trading also initiated coverage with a buy rating and an $11 target.
Bottom Line
Karen Wilson's recent purchase of SER shares adds to her growing interest in the company. Her actions, along with those of other insiders and institutional investors, suggest confidence in SER's prospects. While analysts maintain positive ratings, it's important to remember that these insights are based on past data and may not reflect current positions.
Related Filing Alerts
Source: Karen Wilson's Form 4 filing on $SER (Jun 11, 2026). Find the original filing: SER Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts